Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00813527 | Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels | PHASE2 | COMPLETED | 213 | — | — | Feb 1, 2006 | Jan 1, 2007 | May 24, 2012 | 36 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD | EXPERIMENTAL | - |
| Fenofibrate 145 mg QD | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Lapaquistat acetate and fenofibrate | DRUG | Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks. |
| Fenofibrate | DRUG | Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks. |
Inclusion Criteria: * Women of childbearing potential must not be pregnant as determined by a negative serum human chorionic gonadotropin, not lactating, not planning on becoming pregnant between Screening and 30 days following the last dose of study medication, and agreed to use acceptable forms o...